XenoPort, Inc. (XNPT) - Financial and Strategic SWOT Analysis Review

Summary

XenoPort, Inc. (XenoPort) is a bio-pharmaceutical company with focus on the development and commercialization of internally discovered product candidates for the treatment of neurological disorders. The company develops prodrugs which are created by modification of chemical structure of existing drugs in the market. The company's product pipeline include, XP21279, XP23829 and arbaclofen placarbil for the treatment of gastroesophageal reflux disease, migraine headaches, restless legs syndrome (RLS), neuropathic pain, spasticity related to spinal cord injury and Parkinson’s disease.

XenoPort, Inc. Key Recent Developments

Apr 24, 2013: XenoPort Reports Q1 2013 Results
Mar 11, 2013: XenoPort Reports Revenue Of $21.6m In 2012
Oct 24, 2012: XenoPort Reports Q3 2012 Results
Aug 07, 2012: XenoPort Reports Revenue Of $10.4m For Q2 2012
Jun 04, 2012: XenoPort Names Vincent Angotti As COO

This comprehensive SWOT profile of XenoPort, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. SHOW LESS READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
XenoPort, Inc. - Key Facts
XenoPort, Inc. - Key Employees
XenoPort, Inc. - Key Employee Biographies
XenoPort, Inc. - Major Products and Services
XenoPort, Inc. - Pharmaceutical Pipeline Products Data
XenoPort, Inc., Pipeline Products by Therapy Area
XenoPort, Inc., Pipeline Products by Development Phase
XenoPort, Inc. - History
XenoPort, Inc. - Company Statement
XenoPort, Inc. - Locations And Subsidiaries
Head Office
Section 2 – Company Analysis
XenoPort, Inc. - Business Description
XenoPort, Inc. - Corporate Strategy
XenoPort, Inc. - SWOT Analysis
SWOT Analysis - Overview
XenoPort, Inc. - Strengths
Strength - Strong Intellectual Property Portfolio
Strength - Technological Base
Strength - Strong Research and Development Activities
XenoPort, Inc. - Weaknesses
Weakness - Weak Profitability Position
Weakness - Involvement in Litigations
XenoPort, Inc. - Opportunities
Opportunity - Emerging Markets
Opportunity - Demographic Trends
Opportunity - Market Potential – CNS Therapy
XenoPort, Inc. - Threats
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Threat - Competitive Landscape
XenoPort, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
XenoPort, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
XenoPort, Inc., Recent Developments
Apr 24, 2013: XenoPort Reports Q1 2013 Results
Mar 11, 2013: XenoPort Reports Revenue Of $21.6m In 2012
Oct 24, 2012: XenoPort Reports Q3 2012 Results
Aug 07, 2012: XenoPort Reports Revenue Of $10.4m For Q2 2012
Jun 04, 2012: XenoPort Names Vincent Angotti As COO
May 02, 2012: XenoPort Reports Revenue Of $10.4m In Q1 2012
Feb 14, 2012: XenoPort Reports Revenue Of $5.4m In Q4 2011
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
XenoPort, Inc., Key Facts
XenoPort, Inc., Key Employees
XenoPort, Inc., Key Employee Biographies
XenoPort, Inc., Major Products and Services
XenoPort, Inc., Number of Pipeline Products by Therapy Area
XenoPort, Inc., Number of Pipeline Products by Development Stage
XenoPort, Inc., Pipeline Products By Therapy Area and Development Phase
XenoPort, Inc., History
XenoPort, Inc., Key Competitors
XenoPort, Inc., Ratios based on current share price
XenoPort, Inc., Annual Ratios
XenoPort, Inc., Interim Ratios
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
XenoPort, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
XenoPort, Inc., Pipeline Products by Therapy Area
XenoPort, Inc., Pipeline Products by Development Phase
XenoPort, Inc., Performance Chart (2008 - 2012)
XenoPort, Inc., Ratio Charts
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
XenoPort, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Ivax Corporation
AstraZeneca Pharmaceuticals, LP
Takeda Pharmaceutical Company Limited
IMPAX Laboratories, Inc.
Depomed, Inc.
NeurogesX, Inc.
Mylan Pharmaceuticals Inc.
CorePharma, LLC